Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

Frank Bridoux,Bertrand Arnulf,Lionel Karlin,Nicolas Blin,N. Rabot,Margaret Macro,Vincent Audard,Karim Belhadj,Brigitte Pégourie,P Gobert,Emilie Cornec-Le Gall,Bertrand Joly,Alexandre Karras,Arnaud Jaccard,Karine Augeul-Meunier,Salomon Manier,Bruno Royer,Denis Caillot,Mourad Tiab,Sébastien Delbès,Felipe Suarez,Cécile Vigneau,Sophie Caillard,Nina Arakelyan Laboure,Damien Roos-Weil,Sylvie Chevret,Jean-Paul Fermand

Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy

2020

PURPOSEWe report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy ...

Keywords:

Acute kidney injury
Myeloma cast nephropathy
Randomized controlled trial
Multiple myeloma
Regimen
in patient
Medicine
Bortezomib
Pathology
Urology
Nephropathy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations